CA
NZ
UK
AU
IND
US
Lycia Therapeutics (NASDAQ:LYCA) shares are trading down 6.03% to $27.11 as investors digest the closing of its upsized initial public offering. The company sold 20,286,000 shares at $18.00 each, including the full exercise of the underwriters' option to buy 2,646,000 additional shares, for gross …
Rapport Therapeutics (NASDAQ:RAPP) shares are trading up 9.28% to $27.68 as investors continue to digest positive Phase 2 data for RAP-219 in bipolar mania. The trial met its primary and secondary endpoints, and the company plans to meet the FDA in the first quarter …
Twist Bioscience (NASDAQ:TWST) shares are trading up 10.50% to $160.50 as investors revisit the company's AI-driven drug discovery story ahead of fiscal fourth-quarter results. A small-cap growth investor letter highlighted better-than-expected revenue growth, a raised full-year outlook and rapid growth in AI-related orders, including …
Universal Health Services (NYSE:UHS) shares are trading down 5.75% to $175.04 as hospital stocks sell off after HCA Healthcare (NYSE:HCA) reported third-quarter results. HCA beat estimates, with adjusted EPS of $7.22 against roughly $6.65 expected and revenue of $19.85 billion. Investors focused instead on …
Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares closed at USD 145.04 on October 23, 2026, down 7.07%. The company's most recent quarterly report on file is its Form 10-Q for the period ended June 30, 2026, filed on August 10.
Corcept Therapeutics Incorporated (NASDAQ: CORT) shares closed at USD 85.86 on October 23, 2026, down 20.13%. The commercial-stage biopharmaceutical company began selling its ovarian cancer drug Lifyorli in April, resubmitted its relacorilant application for hypercortisolism to the FDA on June 17 and reported second …
Parabilis Medicines, Inc. (NASDAQ: PBLS) shares closed at USD 24.44 on October 23, 2026, down 9.21%. The clinical-stage company completed its initial public offering in June and filed its first quarterly report as a public company for the period ended June 30, 2026.
Tango Therapeutics, Inc. (NASDAQ: TNGX) shares closed at USD 23.34 on October 23, 2026, down 16.43%. The oncology drug developer reported initial vopimetostat combination data and completed a USD 690.0 million public offering in June, then filed its second quarter 2026 report on August …
Moderna (NASDAQ:MRNA) plunged on Thursday, 22 October 2026, closing down 17.57% at $202.63, the worst performer in the S&P 500, after shares fell as much as 26% intraday on volume well above average. The move followed the leak of personalized melanoma-vaccine data on a …
● AbbVie's lutikizumab showed only a modest benefit in hidradenitis suppurativa.
Please wait processing your request...